Kronos Bio, Inc. (KRON) has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. Dr. Knobelman was previously cFO and head of corporate development for Senti Bio (SNTI).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRON:
- Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
- Kronos Bio reports Q1 EPS (50c), consensus (42c)
- Kronos Bio price target lowered to $2.25 from $2.50 at H.C. Wainwright
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency